SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin.
about
Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes.A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus.Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study.Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.
P2860
Q33781497-EFB8F392-4EF8-4AE0-BDE1-BCC81F0CC32DQ37427304-A7FB3B3D-1350-4D0B-AFA0-AE40F334F3E6Q37588842-EE50ED5F-A5AF-4EEB-A12B-FF22E95673C5Q37672448-0065CD0A-A939-4482-82CC-E384A386D161Q40266818-1114BD0A-1439-4D03-BEFB-4927FF5E6DBCQ41258175-94B25683-80C4-4D13-94ED-74057A4D419CQ48274765-A92E8DAA-D4A7-40E9-9D7B-8D2187B693BCQ51246665-3C31C25E-4A35-4E0C-98ED-A550E5CE2D54Q51276351-0282583F-82B2-4C2B-BDB6-C407FD904FCA
P2860
SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
SGLT2 inhibitors - an insulin- ...... betes: focus on canagliflozin.
@ast
SGLT2 inhibitors - an insulin- ...... betes: focus on canagliflozin.
@en
type
label
SGLT2 inhibitors - an insulin- ...... betes: focus on canagliflozin.
@ast
SGLT2 inhibitors - an insulin- ...... betes: focus on canagliflozin.
@en
prefLabel
SGLT2 inhibitors - an insulin- ...... betes: focus on canagliflozin.
@ast
SGLT2 inhibitors - an insulin- ...... betes: focus on canagliflozin.
@en
P2860
P356
P1476
SGLT2 inhibitors - an insulin- ...... betes: focus on canagliflozin.
@en
P2093
Jochen Seufert
P2860
P304
P356
10.2147/DMSO.S90662
P577
2015-11-09T00:00:00Z